We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Regenerative Medical Group provides a remedy for Wound Healing and Erectile Dysfunction (ED) by using non-invasive technology. It partners with clinics to render the service such as reception, treatment rooms and nurses. In addition to the Erectile Dysfunction (ED) market, it has identified wound healing as a new market. Currently, it is working with an experienced NHS/NICE validation team to show its value as a treatment modality. RMG reached revenues of £400k, -56k EBITDA in the financial year 2017, and is operational in 5 clinics.
days to go: Expired investment: £67,740
MyFirstUK is a car insurance platform for first time driver. It aims to offer young people the perfect cover at the right price and also provide them with all of the guidance they need to make an informed decision. 
days to go: Expired investment: £61,920
Propio offers The Property ISA, a tax-efficient, simple and affordable way to invest in properties. The company aims to become the UK’s largest property-based ISA by making the experience of investing as straightforward as online shopping. Propio is powered by a team of property and finance heavyweights who hand-select all the investments, helping the customers reduce risks and earn stable, tax-free returns, irrespective of market fluctuation. The company’s client base comprises 1000+ customers who have invested over £7.5m in it. According to TrustPilot, Propio is among the top 10 investment companies in the UK, delivering average returns of 6.5% to investors, despite Brexit and stock market turmoil. Moreover, the company has partnered with two UK finance and property firms and expects an investment deal flow of up to £100m by 2021-22.
days to go: Expired investment: £357,660
Loanpad is a financial technology entity that provides a user-friendly, lower-risk platform for investors to earn inflation-busting interest through shared short-term property loans. It argues that its portal shields customers from much of the risk of peer-to-peer (P2P) lending by partnering with established property lenders, who take on both higher risk and return. Investors can invest through Loanpad's Classic and/or Premium accounts (both ISA eligible). The Classic account pays 3% and allows daily withdrawals, while the Premium account pays 4% and requires a 60-day notice for withdrawals. Loanpad has over £22 million in funds under management, onboarded over 2,600 registered investors, and witnessed over 150% growth in loans through 2020. It is authorised by the Financial Conduct Authority (FCA). It will use the investment to boost marketing, further develop software capabilities, increase the size of its Interest Cover Fund (ICF), and invest in general working capital.
days to go: Expired investment: £423,060
For Good Causes turn Loyalty points into donations for charities, giving people a new way to give to causes closest to their hearts. Brands are given a while new CSR opportunity and charities are given much-needed funding. Research has shown their is over £7bn unused rewards in the UK, values which could be donated.
days to go: Expired investment: £292,220
Chip is a wealth investing & savings app that aims to foster financial prosperity for today's generation
days to go: Expired investment: £5,083,686
The British Journal of Photography (BJP) is a monthly magazine dedicated to comtemporary photography. In the last 3 years, the print magazine has been completely re-designed and since then, BJP have launched new apps, new events and awards aimed at capturing the next generation of readers. 
days to go: Expired investment: £399,720
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph